Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Lebrun Labs LLC is currently engaged in the prosecution of 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action represents the entirety of the company's current active workload at the USPTO. Because the portfolio is limited to 1 pending office action, the prosecution strategy is highly focused on a specific technical advancement rather than a diverse set of filings.
The examination of this matter is being conducted by 1 distinct examiner, CLARKE, TRENT R. This individual is also identified as the busiest examiner for the portfolio, as he is responsible for the 1 pending office action currently in the system. Furthermore, the proceedings are localized within 1 distinct art unit, indicating a narrow technical focus for the company's current patenting efforts in the Biotechnology & Pharmaceuticals field.
For a practitioner, the alignment of 1 distinct examiner and 1 distinct art unit for the 1 pending office action creates a very straightforward prosecution landscape. There is no need to coordinate between different examiners or art units, allowing for a direct and consistent communication channel with CLARKE, TRENT R. This concentration simplifies the management of the portfolio by focusing all resources on a single point of contact at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 1 | 42.2% | +24.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18481774 | MATERIALS AND METHODS TO IMPROVE IN VITRO TOXICITY PREDICTIONS | CLARKE, TRENT R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18481774 | MATERIALS AND METHODS TO IMPROVE IN VITRO TOXICITY PREDICTIONS | CLARKE, TRENT R | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18481774 | MATERIALS AND METHODS TO IMPROVE IN VITRO TOXICITY PREDICTIONS | CLARKE, TRENT R | 1651 | §101§102§112 | Final Rejection | — | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLebrun Labs LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Trent R Clarke has the most, with 1 of Lebrun Labs LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
